EBS News and Press, Emergent Biosolutions Inc. From 05/01/24

First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million Updates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) ...

2024-05-01 16:24:49 ET More on Emergent Biosolutions New CEO Appointment A Clear Positive For Emergent BioSolutions Emergent Biosolutions Q1 2024 Earnings Preview Emergent BioSolutions receives NAI status for Baltimore Bayview manufacturing facility Read th...

Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficiently Reorganization will align with evolving business goals, strategic priorities and new operational plan Overall efforts expected to deliver...

Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYS...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility. “In light of this amendment, Emergent now has an extended runw...

2024-04-30 17:20:18 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Call Transcript Emergent BioSolutions Inc. 2023 Q4 - Results - Earnings Call Presentation New CEO Appointment A Clear Positive For Emergent BioSolutions Eme...

2024-04-24 11:01:15 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health sues Amneal Pharma over Xifaxan generic Amneal...

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of...

WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...